CTOs on the Move

Singulex

www.singulex.com

 
Singulex is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.singulex.com
  • 1701 Harbor Bay Parkway
    Alameda, CA USA 94502
  • Phone: 510.995.9000

Executives

Name Title Contact Details

Similar Companies

Oxyband Technologies

Oxyband Technologies, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GluStitch

GluStitch, Inc. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atossa Genetics

Atossa Genetics is a healthcare company offering proprietary medical devices and laboratory services in women`s health. Our laboratory services are offered through our wholly owned subsidiary, the National Reference Laboratory for Breast Health (NRLBH)

Alexza Pharmaceuticals

Alexza Pharmaceuticals, located in Mountain View, CA, is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza`s products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

Vaxxas

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology. In addition to HD-MAP HexaPro clinical studies of a COVID-19 vaccine patch, Vaxxas is performing demonstration work in preparation for clinical evaluation under contract with the United States Biomedical Advanced Research and Development Authority (BARDA) on pandemic vaccination solutions. Vaxxas core technology was initially developed at the University of Queensland. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Partners, Brandon BioCatalyst, and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.